Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.69 - $12.49 $2,676 - $4,996
-400 Reduced 12.5%
2,800 $18,000
Q2 2024

Aug 14, 2024

BUY
$10.5 - $14.81 $31,500 - $44,430
3,000 Added 1500.0%
3,200 $37,000
Q1 2024

May 15, 2024

BUY
$5.34 - $11.09 $1,068 - $2,218
200 New
200 $2,000

Others Institutions Holding GHRS

About GH Research PLC


  • Ticker GHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,020,800
  • Market Cap $370M
  • Description
  • GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...
More about GHRS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.